Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot randomized crossover trial of very-low-dose multi-drug antihypertensive regimens versus moderate-dose irbesartan + hydrochlorothiazide
ACTRN12618001625268Phase 3Not yet recruiting
- Sponsor
- Beyond Community & Health Foundation
- Start
- Nov 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of amlodipine, hydrochlorothiazide, spironolactone, perindopril, bisoprolol and 1 more in systemic hypertension and hypertension (HTN) (6 arms), sponsored by Beyond Community & Health Foundation. Primary endpoint: Adverse events. Planned start Nov 2018; status: not yet recruiting.
02
Drugs
amlodipinehydrochlorothiazidespironolactoneperindoprilbisoprolol
03
Conditions
systemic hypertensionhypertension (HTN)
Beyond the preview
Go deeper on ACTRN12618001625268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001625268.